Association study of MIA3 rs17465637 polymorphism with cardiovascular disease in rheumatoid arthritis patients

Mercedes García-Bermúdez1, Raquel López-Mejías, Carlos González-Juanatey

  • 1Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain.

Insights

The MIA3 rs17465637 A allele may increase cardiovascular event risk in rheumatoid arthritis (RA) patients with dyslipidemia. Further research is needed to confirm the MIA3 gene

Area of Science:

  • Genetics and Cardiovascular Disease
  • Rheumatology and Immunology

Background:

  • Rheumatoid arthritis (RA) is linked to accelerated atherosclerosis.
  • Melanoma inhibitor protein 3 (MIA3) gene variants have been associated with cardiovascular disease.
  • The role of MIA3 in RA-associated cardiovascular complications is unclear.

Purpose of the Study:

  • To investigate the association of the MIA3 rs17465637 polymorphism with cardiovascular disease in Spanish rheumatoid arthritis patients.
  • To evaluate subclinical atherosclerosis markers in relation to the MIA3 polymorphism.

Main Methods:

  • Genotyping of the MIA3 rs17465637 polymorphism in 1505 RA patients.
  • Stratification based on cardiovascular disease presence.
  • Carotid and brachial ultrasonography to assess subclinical atherosclerosis and endothelial dysfunction.

Main Results:

  • A trend for association between MIA3 rs17465637 allele A and carotid plaques (p=0.07).
  • Significant association of the MIA3 rs17465637 A allele with cardiovascular event risk in RA patients with dyslipidemia (p=0.018).
  • No other significant associations found between the MIA3 allele A and cardiovascular events or atherosclerosis markers.

Conclusions:

  • The MIA3 rs17465637 polymorphism may be associated with cardiovascular disease risk in rheumatoid arthritis patients, particularly those with dyslipidemia.
  • Further studies are required to elucidate the role of MIA3 in RA-associated atherogenesis.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Imaging Studies for Cardiovascular System IV: CMRI01:21

Imaging Studies for Cardiovascular System IV: CMRI

Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...